Dose escalation studies are pivotal in the early phases of clinical drug development for evaluating the safety profile of a new therapeutic agent and identifying a recommended dose for further investigation. These studies lay the groundwork for understanding the pharmacokinetic...
Expertise: Oncology & Hematology 102 results
Adaptive design is a progressive approach that utilizes different statistical modeling to allow for modifications to enrollment in a clinical trial after study initiation without undermining data integrity and validity. This methodology is particularly beneficial and increasingly common in phase...
Oncology & Hematology
Transformative Advances in Cancer Immunotherapy: Progress and Promise
Immunotherapy, which engages and harness the body’s own immune system to fight cancer, has revolutionized the field of oncology. Among the most promising immunotherapy approaches are immune checkpoint blockade, adoptive cell therapies, therapeutic vaccines, oncolytic viruses, and mono, bi and...
Oncology & Hematology
Patient-Centered Hematological Malignancy Trials: A Blueprint for Success
Hematological malignancies are a diverse group of cancers that affect the blood, bone marrow, lymph nodes, and spleen. The complexity and variability of these diseases demand innovative and personalized approaches to treatment that traditional clinical trial methodologies often lack. Designing...
MORRISVILLE, N.C., November 6, 2023 — Premier Research announced today the addition of Elaina N. Haeuber, M.S. as Senior Vice President, Oncology. Women now lead all therapeutic specialty teams at Premier Research. “We continue to expand and deepen our oncology...
Oncology & Hematology
Elaina N. Haeuber, M.S.
In the field of oncology, as we got better at understanding the changes that occur in cancers at a molecular level, we have seen a shift towards precision medicine. Biomarkers are central to this change and can be leveraged to...
Oncology & Hematology
Operationalizing Biomarker-Guided Oncology Trials: Planning for Success
Advances in genomic and proteomic technologies have led to the identification of numerous biomarkers with potential clinical utility in oncology, including gene mutations, gene amplifications, gene expression signatures, and altered proteins. To date, more than 1,500 potential oncology biomarkers have...
Oncology & Hematology